Arvinas (NASDAQ:ARVN) Hits New 52-Week Low – Time to Sell?

Arvinas, Inc. (NASDAQ:ARVN) shares hit a new 52-week low on Monday . The company traded as low as $17.34 and last traded at $17.53, with a volume of 309175 shares. The stock had previously closed at $18.62.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ARVN shares. Stephens started coverage on shares of Arvinas in a research note on Monday, November 18th. They issued an “overweight” rating and a $55.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of Arvinas in a research note on Thursday, December 12th. Oppenheimer decreased their price objective on Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $87.00 target price on shares of Arvinas in a report on Wednesday, December 11th. Finally, BMO Capital Markets reduced their price target on Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 20th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $63.50.

Arvinas Stock Up 3.0 %

The company has a market cap of $1.22 billion, a PE ratio of -3.80 and a beta of 1.87. The company’s fifty day moving average is $22.21 and its 200-day moving average is $24.73.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.20. The business had revenue of $102.40 million for the quarter, compared to the consensus estimate of $60.56 million. During the same quarter last year, the firm posted ($1.18) earnings per share. The business’s quarterly revenue was up 196.0% compared to the same quarter last year. Equities research analysts expect that Arvinas, Inc. will post -3.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Arvinas

A number of institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC bought a new stake in Arvinas during the third quarter valued at about $39,000. Quest Partners LLC bought a new position in shares of Arvinas during the 2nd quarter valued at approximately $42,000. Amalgamated Bank grew its stake in shares of Arvinas by 29.6% during the 2nd quarter. Amalgamated Bank now owns 2,223 shares of the company’s stock valued at $59,000 after acquiring an additional 508 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after acquiring an additional 440 shares during the period. Finally, Quantbot Technologies LP lifted its holdings in Arvinas by 147.3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after purchasing an additional 2,601 shares in the last quarter. 95.19% of the stock is owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.